

Xiangguo Qiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5066665/publications.pdf>

Version: 2024-02-01

120
papers

6,287
citations

70961

41
h-index

74018

75
g-index

123
all docs

123
docs citations

123
times ranked

7069
citing authors

#	ARTICLE	IF	CITATIONS
1	Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia. <i>Journal of Infectious Diseases</i> , 2022, 225, 1852-1855.	1.9	1
2	Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. <i>Hepatology</i> , 2022, 76, 330-344.	3.6	11
3	Ta δ Forest Virus Does Not Cause Lethal Disease in Ferrets. <i>Microorganisms</i> , 2021, 9, 213.	1.6	4
4	Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop. <i>MBio</i> , 2021, 12, .	1.8	10
5	Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. <i>Nature Biotechnology</i> , 2021, 39, 747-753.	9.4	38
6	Characterization of Ebola Virus Risk to Bedside Providers in an Intensive Care Environment. <i>Microorganisms</i> , 2021, 9, 498.	1.6	1
7	OUP accepted manuscript. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	1
8	Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. <i>MAbs</i> , 2020, 12, 1742457.	2.6	18
9	The Ferret as a Model for Filovirus Pathogenesis and Countermeasure Evaluation. <i>ILAR Journal</i> , 2020, 61, 62-71.	1.8	14
10	Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008817.	1.3	8
11	Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus. , 2020, 14, e0008817.		0
12	Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus. , 2020, 14, e0008817.		0
13	Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus. , 2020, 14, e0008817.		0
14	Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus. , 2020, 14, e0008817.		0
15	Virus inoculation and treatment regimens for evaluating anti-filovirus monoclonal antibody efficacy in vivo. <i>Biosafety and Health</i> , 2019, 1, 6-13.	1.2	3
16	Peste des Petits Ruminants Virus-Like Particles Induce a Potent Humoral and Cellular Immune Response in Goats. <i>Viruses</i> , 2019, 11, 918.	1.5	8
17	The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development. <i>Viruses</i> , 2019, 11, 999.	1.5	29
18	Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses. <i>PLoS ONE</i> , 2019, 14, e0216949.	1.1	12

#	ARTICLE	IF	CITATIONS
19	The Cytokine Response Profile of Ebola Virus Disease in a Large Cohort of Rhesus Macaques Treated With Monoclonal Antibodies. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz046.	0.4	8
20	Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies. <i>Viruses</i> , 2019, 11, 259.	1.5	5
21	Characterization of Reston virus infection in ferrets. <i>Antiviral Research</i> , 2019, 165, 1-10.	1.9	11
22	Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. <i>PLoS Pathogens</i> , 2019, 15, e1007564.	2.1	20
23	Noncovalent SUMO-interaction motifs in HIV integrase play important roles in SUMOylation, cofactor binding, and virus replication. <i>Virology Journal</i> , 2019, 16, 42.	1.4	10
24	Intra-host Ebola viral adaption during human infection. <i>Biosafety and Health</i> , 2019, 1, 14-24.	1.2	9
25	Identification of a clinical compound losmapimod that blocks Lassa virus entry. <i>Antiviral Research</i> , 2019, 167, 68-77.	1.9	17
26	Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines. <i>Journal of Infectious Diseases</i> , 2019, 219, 544-555.	1.9	30
27	Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease. <i>Journal of Virology</i> , 2019, 93, .	1.5	14
28	HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production. <i>Antiviral Research</i> , 2019, 161, 20-27.	1.9	4
29	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. <i>Cell Host and Microbe</i> , 2019, 25, 39-48.e5.	5.1	83
30	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. <i>Cell Host and Microbe</i> , 2019, 25, 49-58.e5.	5.1	82
31	Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. <i>Nature Communications</i> , 2019, 10, 105.	5.8	45
32	Naturally Occurring Single Mutations in Ebola Virus Observably Impact Infectivity. <i>Journal of Virology</i> , 2019, 93, .	1.5	28
33	Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model. <i>Intensive Care Medicine Experimental</i> , 2019, 7, 54.	0.9	11
34	Small Animal Models for Evaluating Filovirus Countermeasures. <i>ACS Infectious Diseases</i> , 2018, 4, 673-685.	1.8	12
35	Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3582-3594.	2.9	32
36	Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. <i>Antiviral Research</i> , 2018, 151, 39-49.	1.9	23

#	ARTICLE	IF	CITATIONS
37	Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice. <i>Journal of Infectious Diseases</i> , 2018, 217, 916-925.	1.9	37
38	Testing Experimental Therapies in a Guinea Pig Model for Hemorrhagic Fever. <i>Methods in Molecular Biology</i> , 2018, 1604, 269-278.	0.4	1
39	Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections. <i>Human Gene Therapy</i> , 2018, 29, 452-466.	1.4	13
40	Funding vaccines for emerging infectious diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1760-1762.	1.4	11
41	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 159-173.	1.4	35
42	In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. <i>Cell Reports</i> , 2018, 25, 1982-1993.e4.	2.9	38
43	Modeling Ebola Virus Transmission Using Ferrets. <i>MSphere</i> , 2018, 3, .	1.3	16
44	Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever. <i>Antiviral Research</i> , 2018, 160, 87-93.	1.9	27
45	Equine immunoglobulin F(ab ²) fragments protect mice from Rift Valley fever virus infection. <i>International Immunopharmacology</i> , 2018, 64, 217-222.	1.7	3
46	Cellular-Beacon-Mediated Counting for the Ultrasensitive Detection of Ebola Virus on an Integrated Micromagnetic Platform. <i>Analytical Chemistry</i> , 2018, 90, 7310-7317.	3.2	22
47	Marburg and Ravn Virus Infections Do Not Cause Observable Disease in Ferrets. <i>Journal of Infectious Diseases</i> , 2018, 218, S471-S474.	1.9	14
48	The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets. <i>Journal of Infectious Diseases</i> , 2018, 218, S466-S470.	1.9	12
49	Postexposure Protective Efficacy of T-705 (Favipiravir) Against Sudan Virus Infection in Guinea Pigs. <i>Journal of Infectious Diseases</i> , 2018, 218, S649-S657.	1.9	9
50	Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein. <i>Clinical and Experimental Vaccine Research</i> , 2018, 7, 119.	1.1	3
51	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.	5.1	182
52	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. <i>Cell</i> , 2018, 174, 938-952.e13.	13.5	173
53	Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. <i>Cell Discovery</i> , 2018, 4, 31.	3.1	128
54	Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. <i>Scientific Reports</i> , 2017, 7, 43776.	1.6	31

#	ARTICLE	IF	CITATIONS
55	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebola Virus. <i>Cell Reports</i> , 2017, 19, 413-424.	2.9	66
56	Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo. <i>Antiviral Research</i> , 2017, 138, 22-31.	1.9	17
57	Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time. <i>Scientific Reports</i> , 2017, 7, 3390.	1.6	14
58	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. <i>Cell</i> , 2017, 169, 878-890.e15.	13.5	145
59	Immunization-Elicited Broadly Protective Antibody Reveals Ebola Virus Fusion Loop as a Site of Vulnerability. <i>Cell</i> , 2017, 169, 891-904.e15.	13.5	103
60	Delivering Prolonged Intensive Care to a Non-human Primate: A High Fidelity Animal Model of Critical Illness. <i>Scientific Reports</i> , 2017, 7, 1204.	1.6	10
61	Assessing Antiviral Countermeasures Using Mouse Models of Ebola Virus Infection. <i>Methods in Molecular Biology</i> , 2017, 1628, 273-282.	0.4	2
62	How can Ebola virus infection lead to endothelial dysfunction and coagulopathy?. <i>Future Virology</i> , 2017, 12, 89-92.	0.9	1
63	Ultrasensitive Ebola Virus Detection Based on Electroluminescent Nanospheres and Immunomagnetic Separation. <i>Analytical Chemistry</i> , 2017, 89, 2039-2048.	3.2	58
64	Clinical Evaluation of Ebola Virus Disease Therapeutics. <i>Trends in Molecular Medicine</i> , 2017, 23, 820-830.	3.5	17
65	Antiviral activity of quercetin-3-O-D-glucoside against Zika virus infection. <i>Virologica Sinica</i> , 2017, 32, 545-547.	1.2	73
66	Dual-Signal Readout Nanospheres for Rapid Point-of-Care Detection of Ebola Virus Glycoprotein. <i>Analytical Chemistry</i> , 2017, 89, 13105-13111.	3.2	128
67	Synergistic drug combination effectively blocks Ebola virus infection. <i>Antiviral Research</i> , 2017, 137, 165-172.	1.9	75
68	Characterization of Sudan Ebola virus infection in ferrets. <i>Oncotarget</i> , 2017, 8, 46262-46272.	0.8	26
69	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. <i>Science Translational Medicine</i> , 2016, 8, 329ra33.	5.8	78
70	Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. <i>Science Translational Medicine</i> , 2016, 8, 369ra179.	5.8	194
71	Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus. <i>Methods in Molecular Biology</i> , 2016, 1403, 245-257.	0.4	6
72	Spread of ZIKV and YFV to China: Potential implications. <i>Journal of Infection</i> , 2016, 73, 289-291.	1.7	3

#	ARTICLE	IF	CITATIONS
73	An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2016, 214, S326-S332.	1.9	28
74	Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 24179.	1.6	33
75	Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. <i>Journal of Infectious Diseases</i> , 2016, 214, S281-S289.	1.9	30
76	More Challenges From Ebola: Infection of the Central Nervous System. <i>Journal of Infectious Diseases</i> , 2016, 214, S294-S296.	1.9	15
77	The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies. <i>Journal of Virology</i> , 2016, 90, 11075-11086.	1.5	21
78	Potent neutralizing monoclonal antibodies against Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 25856.	1.6	46
79	Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease. <i>Journal of Virology</i> , 2016, 90, 9209-9223.	1.5	63
80	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. <i>Cell Reports</i> , 2016, 15, 1514-1526.	2.9	80
81	Can Ebola virus become endemic in the human population?. <i>Protein and Cell</i> , 2016, 7, 4-6.	4.8	6
82	Prophylactic Efficacy of Quercetin 3- β -D-Glucoside against Ebola Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5182-5188.	1.4	77
83	Progression of Ebola Therapeutics During the 2014-2015 Outbreak. <i>Trends in Molecular Medicine</i> , 2016, 22, 164-173.	3.5	67
84	Antibody therapeutics for Ebola virus disease. <i>Current Opinion in Virology</i> , 2016, 17, 45-49.	2.6	45
85	Diagnostic strategies for Ebola virus detection. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 294-295.	4.6	6
86	Development and Characterization of a Guinea Pig-Adapted Sudan Virus. <i>Journal of Virology</i> , 2016, 90, 392-399.	1.5	42
87	The emergence of antibody therapies for Ebola. <i>Human Antibodies</i> , 2015, 23, 49-56.	0.6	37
88	Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. <i>Journal of Infectious Diseases</i> , 2015, 212, S435-S442.	1.9	9
89	Modelling the effect of early detection of Ebola. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 148-149.	4.6	46
90	Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. <i>Antiviral Research</i> , 2015, 116, 17-19.	1.9	17

#	ARTICLE	IF	CITATIONS
91	Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. <i>Journal of Infectious Diseases</i> , 2015, 212, S389-S397.	1.9	18
92	Development of experimental and early investigational drugs for the treatment of Ebola virus infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 999-1011.	1.9	7
93	Immune Response to Marburg Virus Angola Infection in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2015, 212, S234-S241.	1.9	34
94	Nanozyme-strip for rapid local diagnosis of Ebola. <i>Biosensors and Bioelectronics</i> , 2015, 74, 134-141.	5.3	320
95	Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2015, 212, S379-S383.	1.9	18
96	Ebola Virus Transmission in Guinea Pigs. <i>Journal of Virology</i> , 2015, 89, 1314-1323.	1.5	46
97	VSV-G/EBOV GP-Induced Innate Protection Enhances Natural Killer Cell Activity to Increase Survival in a Lethal Mouse Adapted Ebola Virus Infection. <i>Viral Immunology</i> , 2015, 28, 51-61.	0.6	28
98	The Multiple Roles of sGP in Ebola Pathogenesis. <i>Viral Immunology</i> , 2015, 28, 3-9.	0.6	77
99	A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. <i>Molecular Pharmaceutics</i> , 2015, 12, 2712-2731.	2.3	46
100	Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. <i>Journal of Clinical Investigation</i> , 2015, 125, 4421-4428.	3.9	102
101	Antibody therapy for Ebola. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 964-967.	1.4	15
102	Retrospective Studies: Excellent Tools to Complement Surveillance. <i>Journal of Infectious Diseases</i> , 2014, 209, 811-812.	1.9	0
103	Structures of protective antibodies reveal sites of vulnerability on Ebola virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17182-17187.	3.3	173
104	Establishment and Characterization of a Lethal Mouse Model for the Angola Strain of Marburg Virus. <i>Journal of Virology</i> , 2014, 88, 12703-12714.	1.5	46
105	Characterization of host immune responses in Ebola virus infections. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 781-790.	1.3	78
106	Comprehensive Functional Analysis of N-Linked Glycans on Ebola Virus GP1. <i>MBio</i> , 2014, 5, e00862-13.	1.8	93
107	Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. <i>Vaccine</i> , 2014, 32, 5722-5729.	1.7	66
108	Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. <i>Nature</i> , 2014, 514, 47-53.	13.7	883

#	ARTICLE	IF	CITATIONS
109	Post-exposure therapy of filovirus infections. <i>Trends in Microbiology</i> , 2014, 22, 456-463.	3.5	58
110	Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. <i>Scientific Reports</i> , 2014, 4, 5824.	1.6	39
111	Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus. <i>Scientific Reports</i> , 2014, 4, 6881.	1.6	90
112	Monoclonal Antibodies Combined with Adenovirus-Vectored Interferon Significantly Extend the Treatment Window in Ebola Virus-Infected Guinea Pigs. <i>Journal of Virology</i> , 2013, 87, 7754-7757.	1.5	24
113	Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. <i>Scientific Reports</i> , 2013, 3, 3365.	1.6	93
114	mAbs and Ad-Vectored IFN- β Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms. <i>Science Translational Medicine</i> , 2013, 5, 207ra143.	5.8	106
115	Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates. <i>Science Translational Medicine</i> , 2012, 4, 158ra146.	5.8	135
116	Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies. <i>Science Translational Medicine</i> , 2012, 4, 138ra81.	5.8	274
117	Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1575.	1.3	90
118	Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. <i>Clinical Immunology</i> , 2011, 141, 218-227.	1.4	116
119	Mucosal Immunization of Cynomolgus Macaques with the VS β 1 β G/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses. <i>PLoS ONE</i> , 2009, 4, e5547.	1.1	130
120	Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. <i>Journal of Virological Methods</i> , 2007, 143, 29-37.	1.0	41